Mirum Pharmaceuticals (MIRM) Expected to Announce Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) is anticipated to release its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.05) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 26, 2026 at 4:00 PM ET.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock opened at $102.83 on Wednesday. The firm has a fifty day simple moving average of $87.83 and a two-hundred day simple moving average of $76.82. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. Mirum Pharmaceuticals has a twelve month low of $36.88 and a twelve month high of $105.74. The company has a market capitalization of $5.28 billion, a PE ratio of -119.57 and a beta of 0.49.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 968 shares of the firm’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $103.30, for a total transaction of $99,994.40. Following the sale, the senior vice president owned 4,503 shares in the company, valued at approximately $465,159.90. This trade represents a 17.69% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Eric Bjerkholt sold 1,053 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $101,288.07. Following the completion of the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This trade represents a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MIRM. CIBC Private Wealth Group LLC purchased a new position in Mirum Pharmaceuticals during the 4th quarter valued at $32,000. Quantbot Technologies LP purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at about $33,000. Comerica Bank boosted its holdings in shares of Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company’s stock valued at $40,000 after buying an additional 278 shares in the last quarter. Quarry LP purchased a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $41,000. Finally, Osaic Holdings Inc. boosted its stake in Mirum Pharmaceuticals by 46.5% in the second quarter. Osaic Holdings Inc. now owns 1,106 shares of the company’s stock valued at $56,000 after acquiring an additional 351 shares in the last quarter.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MIRM. HC Wainwright boosted their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Evercore reiterated an “outperform” rating and issued a $101.00 price objective on shares of Mirum Pharmaceuticals in a research report on Tuesday, January 20th. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Citizens Jmp increased their price target on shares of Mirum Pharmaceuticals from $95.00 to $140.00 and gave the company a “market outperform” rating in a research report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $110.17.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.